Qiagen Beats Q3 Outlook, Suspends 2026 Guidance Pending EQT Takeover
QGEN sits 56% above its 52-week low of $32.53.
Summary
Qiagen beat its own Q3 outlook: net sales rose 3% year over year to $548 million and adjusted diluted EPS came in at $0.65, with adjusted operating income margin at 30.4%. Consumables, 91% of sales, grew 3% CER while instruments added 1%; the growth pillars rose 7% CER to $415 million, offset by a 7% CER decline across the rest of the portfolio. The company suspended its 2026 guidance because of the pending EQT Private Equity transaction — the definitive agreement at €46.50 a share in cash was signed October 21 and unanimously approved by both boards. With the stock trading near the deal price, the beat is largely a confirmation of the base business rather than a re-rating event; the guidance suspension removes the standalone outlook as a swing factor. The deal terms, not the quarterly numbers, remain what sets the share price from here.
At the time of this announcement, QGEN was trading at $50.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.5B. The 52-week trading range was $32.53 to $57.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.